MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DISHMAN PHARMA - ASTRAZENECA PHARMA
DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results
DISHMAN PHARMA Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
ASTRAZENECA PHARMA 
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| DISHMAN PHARMA | ASTRAZENECA PHARMA | DISHMAN PHARMA/ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | 152.3 | 16.5% | View Chart |
| P/BV | x | 3.3 | 42.8 | 7.8% | View Chart |
| Dividend Yield | % | 0.7 | 0.0 | - |
Financials
 DISHMAN PHARMA  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
ASTRAZENECA PHARMA Mar-18 |
DISHMAN PHARMA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 1,278 | 29.3% | |
| Low | Rs | 129 | 883 | 14.6% | |
| Sales per share (Unadj.) | Rs | 197.8 | 228.4 | 86.6% | |
| Earnings per share (Unadj.) | Rs | 21.2 | 10.4 | 204.6% | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 16.3 | 213.5% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 179.9 | 98.8 | 182.1% | |
| Shares outstanding (eoy) | m | 80.69 | 25.00 | 322.8% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 4.7 | 26.9% | |
| Avg P/E ratio | x | 11.9 | 104.2 | 11.4% | |
| P/CF ratio (eoy) | x | 7.2 | 66.4 | 10.9% | |
| Price / Book Value ratio | x | 1.4 | 10.9 | 12.8% | |
| Dividend payout | % | 9.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,306 | 27,008 | 75.2% | |
| No. of employees | `000 | 0.8 | 1.4 | 61.1% | |
| Total wages/salary | Rs m | 5,355 | 1,535 | 348.8% | |
| Avg. sales/employee | Rs Th | 19,252.7 | 4,210.9 | 457.2% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 1,132.2 | 570.5% | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 191.1 | 1,080.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 5,710 | 279.5% | |
| Other income | Rs m | 265 | 123 | 216.7% | |
| Total revenues | Rs m | 16,226 | 5,833 | 278.2% | |
| Gross profit | Rs m | 4,103 | 463 | 886.4% | |
| Depreciation | Rs m | 1,091 | 147 | 739.9% | |
| Interest | Rs m | 944 | 0 | - | |
| Profit before tax | Rs m | 2,334 | 438 | 532.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 624 | 179 | 348.6% | |
| Profit after tax | Rs m | 1,711 | 259 | 660.4% | |
| Gross profit margin | % | 25.7 | 8.1 | 317.1% | |
| Effective tax rate | % | 26.7 | 40.8 | 65.4% | |
| Net profit margin | % | 10.7 | 4.5 | 236.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 3,209 | 343.3% | |
| Current liabilities | Rs m | 9,517 | 2,070 | 459.9% | |
| Net working cap to sales | % | 9.4 | 20.0 | 47.1% | |
| Current ratio | x | 1.2 | 1.6 | 74.7% | |
| Inventory Days | Days | 110 | 72 | 152.7% | |
| Debtors Days | Days | 35 | 35 | 99.8% | |
| Net fixed assets | Rs m | 16,304 | 790 | 2,063.0% | |
| Share capital | Rs m | 161 | 50 | 322.8% | |
| "Free" reserves | Rs m | 12,907 | 2,419 | 533.5% | |
| Net worth | Rs m | 14,516 | 2,469 | 587.8% | |
| Long term debt | Rs m | 4,189 | 0 | - | |
| Total assets | Rs m | 29,805 | 4,605 | 647.2% | |
| Interest coverage | x | 3.5 | NM | - | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.5 | 1.2 | 43.2% | |
| Return on assets | % | 8.9 | 5.6 | 158.4% | |
| Return on equity | % | 11.8 | 10.5 | 112.3% | |
| Return on capital | % | 17.5 | 17.7 | 98.8% | |
| Exports to sales | % | 24.8 | 0 | - | |
| Imports to sales | % | 3.7 | 0 | - | |
| Exports (fob) | Rs m | 3,956 | NA | - | |
| Imports (cif) | Rs m | 596 | NA | - | |
| Fx inflow | Rs m | 4,952 | 300 | 1,653.0% | |
| Fx outflow | Rs m | 697 | 2,015 | 34.6% | |
| Net fx | Rs m | 4,255 | -1,715 | -248.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 88 | 3,170.0% | |
| From Investments | Rs m | -1,529 | -94 | 1,633.4% | |
| From Financial Activity | Rs m | -941 | NA | - | |
| Net Cashflow | Rs m | 316 | -6 | -5,550.9% | |
Share Holding
| Indian Promoters | % | 61.4 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 3.7 | 0.3 | 1,233.3% | |
| FIIs | % | 12.7 | 15.7 | 80.9% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 22.1 | 9.1 | 242.9% | |
| Shareholders | 46,261 | 12,856 | 359.8% | ||
| Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: FULFORD INDIA VENUS REMEDIES CIPLA WOCKHARDT SUVEN LIFE SCIENCES
Compare DISHMAN PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Momentum Moves: The Week Gone By(Momentum Moves)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)
Sep 22, 2020 | Updated on Sep 22, 2020For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)
May 20, 2020 | Updated on May 20, 2020For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
More Views on NewsMost Popular
My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)
Jan 5, 2021My new guide will show you the huge potential in future proof businesses.
'Essential' Smallcap Stock Recommendations(Profit Hunter)
Jan 8, 2021The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
Is Nifty Forming a Top(Fast Profits Daily)
Jan 8, 2021The charts are telling the bulls to be cautious.
Why Gold Hit Lower Circuit(Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Five Wishes and a Will(The Honest Truth)
Jan 4, 2021Ajit Dayal on the investing strategy for 2021 and beyond.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA - PROCTER & GAMBLE HEALTH COMPARISON
COMPARE DISHMAN PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.